Skip to main content

Hypoglycemia

6
Pipeline Programs
12
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
3
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
1100%
+ 13 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Prevail Therapeutics
4 programs
1
1
2
Nasal GlucagonPhase 3
Nasal GlucagonPhase 3
Nasal Glucagon 1 mgPhase 2
Nasal GlucagonPhase 1
Abbott
AbbottABBOTT PARK, IL
2 programs
1
GlucernaPhase 31 trial
euglycemic and hypoglycemic clampN/A1 trial
Active Trials
NCT01283126Completed20Est. Oct 2015
NCT03802942Unknown500Est. Dec 2023
Pfizer
PfizerNEW YORK, NY
1 program
1
GlucagenPhase 11 trial
Active Trials
NCT00745186Completed28Est. Mar 2008
UNEEG Medical
UNEEG MedicalDenmark - Allerod
2 programs
EEG-Changes During Insulininduced Hypoglycemia in Type 1 DiabetesN/A1 trial
experimentalN/A1 trial
Active Trials
NCT00810420CompletedEst. Apr 2008
NCT01238016Terminated16Est. Aug 2014
Sanofi
SanofiPARIS, France
1 program
Investigating Novel Predictions of Hypoglycemia Occurrence in Real-world ModelsN/A1 trial
Active Trials
NCT04219514Completed1,206Est. Mar 2021
Fresenius Kabi
Fresenius KabiGermany - Bad Homburg
1 program
Glucagon for InjectionPHASE_11 trial
Active Trials
NCT02086227Completed32Est. Jun 2013
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
DasiglucagonPHASE_31 trial
Active Trials
NCT05378672Completed8Est. Dec 2024
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
Nasal GlucagonPHASE_31 trial
Active Trials
NCT02171130Completed129Est. Aug 2015
Bristol Myers Squibb
1 program
PramlintidePHASE_4Peptide1 trial
Active Trials
NCT01841359Completed22Est. Feb 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bristol Myers SquibbPramlintide
Novo NordiskDasiglucagon
AbbottGlucerna
Eli Lilly and CompanyNasal Glucagon
Fresenius KabiGlucagon for Injection
PfizerGlucagen
SanofiInvestigating Novel Predictions of Hypoglycemia Occurrence in Real-world Models
Abbotteuglycemic and hypoglycemic clamp
UNEEG Medicalexperimental
UNEEG MedicalEEG-Changes During Insulininduced Hypoglycemia in Type 1 Diabetes

Clinical Trials (10)

Total enrollment: 1,961 patients across 10 trials

NCT01841359Bristol Myers SquibbPramlintide

Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery

Start: Feb 2010Est. completion: Feb 202222 patients
Phase 4Completed
NCT05378672Novo NordiskDasiglucagon

A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D

Start: May 2023Est. completion: Dec 20248 patients
Phase 3Completed
NCT03802942AbbottGlucerna

Prevention of Hypoglycemia Among Diabetes Patients Admitted to Internal Medicine Departments With Nutritional Care

Start: Jul 2019Est. completion: Dec 2023500 patients
Phase 3Unknown
NCT02171130Eli Lilly and CompanyNasal Glucagon

Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia

Start: May 2014Est. completion: Aug 2015129 patients
Phase 3Completed
NCT02086227Fresenius KabiGlucagon for Injection

Bioequivalence of Fresenius Kabi USA, LLC Glucagon for SC Injection Compared to Glucagon for Injection (Bedford Laboratories)

Start: May 2013Est. completion: Jun 201332 patients
Phase 1Completed
NCT00745186PfizerGlucagen

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers

Start: Aug 2007Est. completion: Mar 200828 patients
Phase 1Completed
NCT04219514SanofiInvestigating Novel Predictions of Hypoglycemia Occurrence in Real-world Models

Investigating Novel Predictions of Hypoglycemia Occurrence in Real-world Models

Start: Feb 2020Est. completion: Mar 20211,206 patients
N/ACompleted
NCT01283126Abbotteuglycemic and hypoglycemic clamp

Blood/Interstitial Glucose Measurements and Cognitive Function During Hypoglycemia and Recovery

Start: Jan 2011Est. completion: Oct 201520 patients
N/ACompleted
NCT01238016UNEEG Medicalexperimental

Evaluation of Hypo-Safe Hypoglycaemia Alarm Device - a Pilot Study

Start: Nov 2010Est. completion: Aug 201416 patients
N/ATerminated
NCT00810420UNEEG MedicalEEG-Changes During Insulininduced Hypoglycemia in Type 1 Diabetes

EEG-Changes During Insulininduced Hypoglycemia in Type 1 Diabetes

Start: Feb 2007Est. completion: Apr 2008
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
12 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.